Sankyo Sues Nissin Over Mevalotin Patent

Law360, New York (April 20, 2004, 12:00 AM EDT) -- Japanese drug maker Sankyo has filed a lawsuit against domestic rival Nissin Pharmaceutical over its flagship hyperlipidaemia drug Mevalotin (pravastatin), which Sankyo developed after discovering the world’s first cholesterol inhibitor.

Sankyo’s action follows Nissin’s recent launch of a generic version of the product, called Mevarich, following the expiration of Mevalotin's patent in October 2002.

With the main patent expired, Sankyo is suing Nissin based on a patent for the technology to keep Mevalotin tablets stable.

Around 30 companies are currently developing generic versions of Mevalotin with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.